Home > Insider Trading > Filing (0001104659-24-031806)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
886163	Ligand Pharmaceuticals Inc	LGND	Pharmaceutical Preparations (2834)	770160744

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1442372	L Stephen Sabba	Dorset Management Corp 485 Underhill Blvd Suite 205 Syosset NY 11791		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2024-03-05	2,893	$0.00	30,819	No	4	M	Direct
Common Stock	Disposition	2024-03-05	1,893	$74.30	28,926	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Non-Qualified Stock Option (right to buy)	Disposition	2024-03-05	2,893	$0.00	2,893	$67.53

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
419		2024-06-04	No	4	M	Direct

Footnotes

These securities, as represented in Column 5, include a grant of 1,142 restricted share units approved by the Board of Directors of the Company at the 2023 Meeting, which shares will vest in full on the earlier of (a) the date of the next annual meeting of the Company stockholders following the grant date or (b) on the first anniversary of the grant date. They also properly reflect adjustments from the OmniAb Inc. separation from the Issuer. The Shares referenced in Column 5 of Table I as disposed of on the Form 4 filed 5/10/23 for this Reporting Person inadvertently failed correctly to reflect those adjustments. That number should have been 26,784.
These securities, as represented in Column 5, were acquired by a grant of 3,312 shares by the Board of Directors of the Company at the 2014 Meeting. That grant vested in full on the first anniversary of the grant date or immediately (x) upon a change in control or a hostile takeover of the Company or (y) the death or permanent disability of the grantee if still serving at that time.
This Option was previously reported on the Form 4 filed 6/6/14 as a Grant of 3,312 shares, which vested in full on April 24, 2015, at an exercise price of $67.53 per share, but was adjusted pursuant to the OmniAb Inc. separation from the Issuer.